20/20 Biolabs, Inc. (AIDX) Annual Report: A Plain-English Summary

I’ve put together this guide to help you understand how 20/20 Biolabs, Inc. (AIDX) performed this year. My goal is to turn complex financial filings into clear information so you can decide if this company fits your investment goals.

1. What does this company do?

20/20 Biolabs operates four distinct business lines that generate revenue through different channels:

• OneTest: Their core blood test screens for multiple cancer markers simultaneously to detect early-stage disease.
• Longevity: A wellness program that tracks inflammation markers to identify risks for heart disease, metabolic syndrome, and diabetes.
• CLIAx: A "lab-as-a-service" business. They use their certified labs to process tests for biotech startups, charging a recurring fee plus a 10% profit margin.
• BioCheck: A legacy business that sells rapid diagnostic kits to government agencies to screen for biological threats like anthrax.

2. Why their technology matters

The company uses AI and health data from over 2.5 million checkups in East Asia to train their cancer-spotting software. This dataset allows them to achieve over 85% accuracy in early detection while bypassing the multi-year, $50 million clinical trials typically required for such technology. They currently hold 14 patents in the U.S., Japan, and China, which protects their diagnostic methods from competitors.

3. Major Wins and New Directions

• Strong Revenue Growth: Sales for their cancer test grew from $323,000 in 2022 to over $1.8 million in 2025—a 457% increase.
• The "At-Home" Advantage: Unlike competitors who require a professional blood draw, 20/20 uses a simple finger-prick kit. This decentralized approach cuts the cost per test by approximately 60%.
• Strategic Partnerships: They partner with ROKIT Healthcare. By identifying patients with high inflammation, 20/20 refers them to ROKIT’s treatments and earns a 5% commission on those referrals.

4. Key Risks to Consider

Investing in 20/20 involves specific financial and operational challenges:

• The Profitability Gap: While the company was profitable in 2021 and 2022 due to high demand for COVID-19 testing, that revenue stream has ended. They currently operate at a monthly burn rate of approximately $450,000. They recently raised $5 million to fund operations through late 2026.
• Regulatory & Data Risks: Because they handle sensitive health information, they are subject to strict privacy laws. A data breach or failure to maintain lab certifications could result in significant fines or the loss of their ability to operate.
• International Hurdles: Expanding into Asia involves compliance with the Foreign Corrupt Practices Act. Any issues regarding international payments could lead to legal challenges or the loss of operating licenses.
• Dilution: Because the company is not yet self-sustaining, they may issue additional shares to raise capital. If they do not reach a break-even point in the near future, current shareholders could see their ownership percentage decrease by 10–15% over the next 18 months.

Final Thought for Investors: When evaluating this opportunity, weigh the company's impressive 457% growth in their core cancer testing business against their current cash burn. The key to their long-term success will be their ability to scale the OneTest and CLIAx services enough to reach profitability before their current $5 million funding runway expires.